



DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

March 28, 2024

Kiran Asarpota
Chief Operating Officer
ASLAN Pharmaceuticals Ltd
3 Temasek Avenue
Level 18 Centennial Tower
Singapore 039190

Re: ASLAN Pharmaceuticals Ltd
Registration Statement on Form F-3
Filed March 25, 2024
File No. 333-278217

Dear Kiran Asarpota:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Jimmy McNamara at 202-551-7349 with any questions.

Sincerely,

Division of Corporation Finance
Office of Life Sciences

cc: Carlos Ramirez